Mersana Therapeutics Inc (NASDAQ: MRSN) on Friday, plunged -8.05% from the previous trading day, before settling in for the closing price of $1.74. Within the past 52 weeks, MRSN’s price has moved between $1.22 and $6.28.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 12371.94%. The company achieved an average annual earnings per share of 60.21%. With a float of $86.56 million, this company’s outstanding shares have now reached $122.87 million.
Considering the fact that the conglomerate employs 123 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 48.0%, operating margin of -228.07%, and the pretax margin is -212.99%.
Mersana Therapeutics Inc (MRSN) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Mersana Therapeutics Inc is 29.93%, while institutional ownership is 66.09%. The most recent insider transaction that took place on Oct 28 ’24, was worth 3,580. In this transaction SVP, Chief Development Officer of this company sold 1,884 shares at a rate of $1.90, taking the stock ownership to the 54,731 shares. Before that another transaction happened on Oct 28 ’24, when Company’s Officer proposed sale 1,884 for $2.04, making the entire transaction worth $3,843.
Mersana Therapeutics Inc (MRSN) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.17 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 60.21% per share during the next fiscal year.
Mersana Therapeutics Inc (NASDAQ: MRSN) Trading Performance Indicators
Mersana Therapeutics Inc (MRSN) is currently performing well based on its current performance indicators. A quick ratio of 2.35 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 5.22.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.61, a number that is poised to hit -0.15 in the next quarter and is forecasted to reach -0.57 in one year’s time.
Technical Analysis of Mersana Therapeutics Inc (MRSN)
Compared to the last year’s volume of 1.58 million, its volume of 2.07 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 5.67%. Additionally, its Average True Range was 0.26.
During the past 100 days, Mersana Therapeutics Inc’s (MRSN) raw stochastic average was set at 23.60%, which indicates a significant increase from 3.08% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 118.43% in the past 14 days, which was higher than the 109.48% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.1554, while its 200-day Moving Average is $2.4661. Nevertheless, the first resistance level for the watch stands at $1.6664 in the near term. At $1.7327, the stock is likely to face the second major resistance level. The third major resistance level sits at $1.7855. If the price goes on to break the first support level at $1.5473, it is likely to go to the next support level at $1.4945. Should the price break the second support level, the third support level stands at $1.4282.
Mersana Therapeutics Inc (NASDAQ: MRSN) Key Stats
Market capitalization of the company is 181.75 million based on 123,533K outstanding shares. Right now, sales total 36,860 K and income totals -171,670 K. The company made 12,600 K in profit during its latest quarter, and -11,500 K in sales during its previous quarter.
